Status:
UNKNOWN
Gene Polymorphism in Tinea Versicolor
Lead Sponsor:
Kasr El Aini Hospital
Conditions:
Recurrent Pityriasis Versicolor
Eligibility:
All Genders
18-60 years
Brief Summary
Blood samples will be taken from cases presenting with recurrent tinea versicolor , after confirmation of diagnosis by wood's light and KOH examination, for the detection of gene polymorphism in IL17 ...
Eligibility Criteria
Inclusion
- \- Patients with recurrent pityriasis versicolor (active now) and not taking treatment for it.
- Patients of both genders.
- Age ≥18 years old.
Exclusion
- \- Patients with other cutaneous diseases.
- Patient's having dandruff (scaly scalp) even if not symptomatizing.
- Pregnant and lactating females, children, prisoners, cognitively impaired or mentally disabled subjects.
- Patients with autoimmune diseases.
- Patients with immunodeficiency diseases.
- Immunosuppressed patients e.g. HIV, diabetics, organ transplant, malignancy, patients taking immunosuppressive drugs e.g. chemotherapy, cortisone.
Key Trial Info
Start Date :
November 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04769804
Start Date
November 1 2019
End Date
November 1 2021
Last Update
April 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kasr Al Ainy Hospital, Cairo university
Cairo, El Manial, Egypt, 11956